Potassium%252520chloride

# Potassium chloride ## Overview Potassium chloride is a salt used to prevent or treat hypokalemia. It is available in various formulations (extended-release tablets, capsules, powders, liquid, and intravenous concentrates). **Never administer IV potassium undiluted.** ## Primary Indications * Treatment and prophylaxis of hypokalemia. * Management of potassium depletion due to diuretics, corticosteroids, or severe diarrhea/vomiting. ## Adult Dosing * **Oral (Hypokalemia):** 40–100 mEq/day in divided doses. Assess serum K+; rarely exceed 20 mEq per single dose to mitigate GI distress. * **IV (General):** 10–20 mEq/hour. Do not exceed 10 mEq/hour in peripheral lines (to prevent phlebitis). Maximum concentrations typically 40 mEq/L unless in high-acuity settings with central access and continuous cardiac monitoring (max 80 mEq/L). * **IV (Severe/Critical):** Up to 20–40 mEq/hour may be used via central line under strict cardiac monitoring and specialist oversight. ## Pediatric Dosing * **Oral:** 1–3 mEq/kg/day in divided doses, titrated to effect. * **IV (Maintenance/Replacement):** 1–2 mEq/kg/day, not to exceed adult rates (0.5–1 mEq/kg/hour). Maximum concentration in peripheral IV is usually 0.5–1 mEq/mL. * **Note:** Pediatric dosing varies significantly by institutional protocol and fluid status; always verify against local guidelines. ## Dose Adjustments * **Renal Impairment:** Reduce dose or avoid in severe renal impairment (CrCl <30 mL/min) or anuria, as the risk of hyperkalemia is significantly elevated. * **Hepatic Impairment:** No specific adjustment, but use caution if associated with renal compromise. ## Contraindications * Severe renal impairment (anuria, oliguria, azotemia). * Untreated Addison’s disease. * Hyperkalemia. * Conditions where high potassium ingestion/administration is dangerous (e.g., GI obstruction, esophageal compression). ## Adverse Effects * **GI:** Nausea, vomiting, diarrhea, abdominal pain, GI ulceration/bleeding (especially with solid oral dosage forms). * **CV:** Arrhythmias (with rapid IV infusion or hyperkalemia). * **Local:** Phlebitis, site pain, or tissue necrosis if extravasated. ## Key Drug Interactions * **ACE Inhibitors / ARBs:** Increase risk of hyperkalemia. * **Potassium-Sparing Diuretics (e.g., spironolactone, triamterene):** High risk of severe hyperkalemia. * **NSAIDs:** May exacerbate potassium retention via reduced renal perfusion. ## Monitoring * **Serum Potassium:** Before and frequently after initiation. * **Renal Function:** Monitor BUN and Creatinine. * **Cardiac:** ECG monitoring for patients receiving high-dose IV potassium or those with cardiovascular comorbidities. * **Signs of Hyperkalemia:** Muscle weakness, bradycardia, paresthesia, or peaked T-waves. ## Clinical Pearls * **GI Safety:** Advise patients to take oral capsules/tablets with a full glass of water and remain upright for 30 minutes to prevent esophageal ulceration. * **IV Administration:** Ensure IV sites are patent; check for signs of extravasation frequently. * **Calculation:** 1 mEq = 1 mmol. * **Correction:** 10 mEq of potassium chloride typically raises serum potassium by approximately 0.1 mEq/L (varies based on body stores and renal status). *** **Educational Disclaimer:** This information is for educational purposes only and does not replace professional clinical judgment. Always consult institutional protocols, current package inserts, and evidence-based drug databases (e.g., Lexicomp, Micromedex) before prescribing or administering medication.